Prediction of HLA-A2-restricted CTL epitope specific to HCC by SYFPEITHI combined with polynomial method

被引:8
作者
Dong, Hai-Long [1 ]
Sui, Yan-Fang [1 ]
机构
[1] Fourth Mil Med Univ, Dept Pathol, Xian 710032, Shaanxi Provinc, Peoples R China
关键词
Hepatocellular carcinoma; HLA-A*0201; Cytotoxic T Lymphocyte; Epitope;
D O I
10.3748/wjg.v11.i2.208
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To predict the HLA-A2-restricted CTL epitopes of tumor antigens associated with hepatocellular carcinoma (HCC). METHODS: MAGE-1, MAGE-3, MAGE-8, P53 and AFP were selected as objective antigens in this study for the close association with HCC. The HLA-A*0201 restricted CTL epitopes of objective tumor antigens were predicted by SYFPEITHI prediction method combined with the polynomial quantitative motifs method. The threshold of polynomial scores was set to -24. RESULTS: The SYFPEITHI prediction values of all possible nonamers of a given protein sequence were added together and the ten high-scoring peptides of each protein were chosen for further analysis in primary prediction. Thirty-five candidates of CTL epitopes (nonamers) derived from the primary prediction results were selected by analyzing with the polynomial method and compared with reported CTL epitopes. CONCLUSION: The combination of SYFPEITHI prediction method and polynomial method can improve the prediction efficiency and accuracy. These nonamers may be useful in the design of therapeutic peptide vaccine for HCC and as immunotherapeutic strategies against HCC after identified by immunology experiment. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.
引用
收藏
页码:208 / 211
页数:4
相关论文
共 28 条
[1]   Immunotherapy of hepatocellular carcinoma [J].
Butterfield, LH ;
Ribas, A .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (02) :123-133
[2]   T cell responses to HLA-A*0201-restricted peptides derived from human α fetoprotein [J].
Butterfield, LH ;
Meng, WS ;
Koh, A ;
Vollmer, CM ;
Ribas, A ;
Dissette, VB ;
Faull, K ;
Glaspy, JA ;
McBride, WH ;
Economou, JS .
JOURNAL OF IMMUNOLOGY, 2001, 166 (08) :5300-5308
[3]   Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients [J].
Charuruks, N ;
Tangkijvanich, P ;
Voravud, N ;
Chatsantikul, R ;
Theamboonlers, A ;
Poovorawan, Y .
JOURNAL OF GASTROENTEROLOGY, 2001, 36 (12) :830-836
[4]   Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study [J].
Dagher, R ;
Long, LM ;
Read, EJ ;
Leitman, SF ;
Carter, CS ;
Tsokos, M ;
Goletz, TJ ;
Avila, N ;
Berzofsky, JA ;
Helman, LJ ;
Mackall, CL .
MEDICAL AND PEDIATRIC ONCOLOGY, 2002, 38 (03) :158-164
[5]   Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro [J].
Dong, HL ;
Sui, YF ;
Li, ZS ;
Qu, P ;
Wu, W ;
Ye, J ;
Zhang, XM ;
Lu, SY .
CANCER LETTERS, 2004, 211 (02) :219-225
[6]   Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review [J].
Gebo, KA ;
Chander, G ;
Jenckes, MW ;
Ghanem, KG ;
Herlong, HF ;
Torbenson, MS ;
El-Kamary, SS ;
Bass, EB .
HEPATOLOGY, 2002, 36 (05) :S84-S92
[7]   Two complementary methods for predicting peptides binding major histocompatibility complex molecules [J].
Gulukota, K ;
Sidney, J ;
Sette, A ;
DeLisi, C .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 267 (05) :1258-1267
[8]   PRECISE PREDICTION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II PEPTIDE INTERACTION BASED ON PEPTIDE SIDE-CHAIN SCANNING [J].
HAMMER, J ;
BONO, E ;
GALLAZZI, F ;
BELUNIS, C ;
NAGY, Z ;
SINIGAGLIA, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (06) :2353-2358
[9]   NEW METHODS TO PREDICT MHC-BINDING SEQUENCES WITHIN PROTEIN ANTIGENS [J].
HAMMER, J .
CURRENT OPINION IN IMMUNOLOGY, 1995, 7 (02) :263-269
[10]   Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24 [J].
Katsura, F ;
Eura, M ;
Chikamatsu, K ;
Oiso, M ;
Yumoto, E ;
Ishikawa, T .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2000, 30 (03) :117-121